Microsatellite Instability and Adjuvant Chemotherapy in Stage II Colon Cancer

被引:28
作者
Koenig, Julie L. [1 ,2 ]
Toesca, Diego A. S. [1 ]
Harris, Jeremy P. [1 ]
Tsai, Chiaojung Jillian [5 ]
Haraldsdottir, Sigurdis [3 ]
Lin, Albert Y. [2 ,4 ]
Pollon, Erqi L. [1 ]
Chang, Daniel T. [1 ]
机构
[1] Stanford Canc Inst, Dept Radiat Oncol, 875 Blake Wilbur Dr MC5847, Stanford, CA 94305 USA
[2] Stanford Univ, Sch Med, Stanford, CA 94305 USA
[3] Stanford Canc Inst, Dept Internal Med, Stanford, CA 94305 USA
[4] VA Palo Alto Hlth Care Syst, Div Oncol, Dept Internal Med, Palo Alto, CA USA
[5] Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, 1275 York Ave, New York, NY 10021 USA
来源
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS | 2019年 / 42卷 / 07期
关键词
adjuvant chemotherapy; stage II colon cancer; microsatellite instability; tumor sidedness; National Cancer Database; MISMATCH REPAIR; COLORECTAL-CANCER; SURVIVAL; FLUOROURACIL; OXALIPLATIN; LEUCOVORIN; EFFICACY; THERAPY; RESISTANCE; MUTATION;
D O I
10.1097/COC.0000000000000554
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Randomized control trials and population-based studies do not demonstrate a definitive benefit for adjuvant chemotherapy (ACT) in stage II colon cancer (CC). Tumor sidedness and microsatellite instability (MSI) status may predict response to ACT, but previous studies have limited microsatellite data. We assessed the efficacy of ACT and possible interaction with MSI status and tumor sidedness in patients with resected stage II CC diagnosed between 2010 and 2013 using the National Cancer Database. Materials and Methods: Overall survival was evaluated with the Kaplan-Meier method and multivariate and propensity score matched Cox proportional hazards models. The interaction between receipt of ACT, MSI status, and tumor sidedness was evaluated. The efficacy of ACT was assessed in patient subgroups by MSI status and tumor sidedness. Results: Among 6964 stage II CC patients with known MSI status, 1497 (21.5%) received ACT, 843 had MSI tumors, and 6121 had microsatellite stable (MSS) tumors. In multivariate and propensity score matched analyses, ACT was associated with improved survival after adjusting for factors including high-risk features, MSI status, and tumor sidedness (multivariate hazard ratio, 0.52; P<0.001). There was no interaction between receipt of ACT and MSI status (P=0.25). Patients with MSS tumors benefitted from ACT (multivariate hazard ratio, 0.47; P<0.001), even without other high-risk features. Patients with MSI tumors did not (P=0.671). ACT was associated with improved survival regardless of tumor sidedness. Conclusions: MSS alone may warrant ACT in stage II CC while patients with MSI tumors may not derive significant benefit from ACT.
引用
收藏
页码:573 / 580
页数:8
相关论文
共 38 条
  • [1] Aebi S, 1996, CANCER RES, V56, P3087
  • [2] Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study
    Andre, Thierry
    de Gramont, Armand
    Vernerey, Dewi
    Chibaudel, Benoist
    Bonnetain, Franck
    Tijeras-Raballand, Annemilai
    Scriva, Aurelie
    Hickish, Tamas
    Tabernero, Josep
    Van Laethem, Jean Luc
    Banzi, Maria
    Maartense, Eduard
    Shmueli, Einat
    Carlsson, Goran U.
    Scheithauer, Werner
    Papamichael, Demetris
    Moeehler, Marcus
    Landolfi, Stefania
    Demetter, Pieter
    Colote, Soudhir
    Tournigand, Christophe
    Louvet, Christophe
    Duval, Alex
    Flejou, Jean-Francois
    de Gramont, Aimery
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (35) : 4176 - +
  • [3] Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial
    Andre, Thierry
    Boni, Corrado
    Navarro, Matilde
    Tabernero, Josep
    Hickish, Tamas
    Topham, Clare
    Bonetti, Andrea
    Clingan, Philip
    Bridgewater, John
    Rivera, Fernando
    de Gramont, Aimery
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (19) : 3109 - 3116
  • [4] [Anonymous], NAT CANC DAT BAS NCD
  • [5] [Anonymous], FACT SHEETS POP GLOB
  • [6] Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies
    Austin, Peter C.
    [J]. PHARMACEUTICAL STATISTICS, 2011, 10 (02) : 150 - 161
  • [7] Assessing balance in measured baseline covariates when using many-to-one matching on the propensity-score
    Austin, Peter C.
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2008, 17 (12) : 1218 - 1225
  • [8] American society of clinical oncology recommendations on adjuvant chemotherapy for stage II colon cancer
    Benson, AB
    Schrag, D
    Somerfield, MR
    Cohen, AM
    Figueredo, AT
    Flynn, PJ
    Krzyzanowska, MK
    Maroun, J
    McAllister, P
    Van Cutsem, E
    Brouwers, M
    Charette, M
    Haller, DG
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (16) : 3408 - 3419
  • [9] Path Toward Prognostication and Prediction: An Evolving Matrix
    Benson, Al B., III
    Hamilton, Stanley R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (35) : 4599 - 4601
  • [10] Microsatellite Instability and Loss of Heterozygosity at Chromosomal Location 18q: Prospective Evaluation of Biomarkers for Stages II and III Colon Cancer-A Study of CALGB 9581 and 89803
    Bertagnolli, Monica M.
    Redston, Mark
    Compton, Carolyn C.
    Niedzwiecki, Donna
    Mayer, Robert J.
    Goldberg, Richard M.
    Colacchio, Thomas A.
    Saltz, Leonard B.
    Warren, Robert S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (23) : 3153 - 3162